GlassScriptPhysician profile
Bradley Sumrall
NPI 1679689301
$35,783.85
in general payments reported to CMS, 2019-2025
64 companies · $4,793 in 2025
The $4,793 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $5,341 · 2020: $6,177 · 2021: $10K · 2022: $5,700 · 2023: $2,096 · 2024: $1,665 · 2025: $4,793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,592 · Food and Beverage: $3,947 · Education: $16.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,591.50 |
| Food and Beverage | $3,946.60 |
| Education | $16.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $7,912.58 | 2019-2025 | Lynparza, Calquence |
| Gilead Sciences, INC. | $4,761.00 | 2019-2025 | Trodelvy |
| Amgen INC. | $3,489.36 | 2019-2023 | Lumakras, Kyprolis, Blincyto |
| Janssen Biotech, INC. | $2,652.99 | 2019-2025 | Talvey, Tecvayli, Darzalex |
| Kite Pharma, INC. | $1,793.79 | 2021-2025 | Yescarta |
| Eisai INC. | $1,585.56 | 2019-2024 | |
| Seagen INC. | $1,585.55 | 2019-2023 | Tukysa |
| Celgene Corporation | $1,541.63 | 2019-2024 | Reblozyl, Pomalyst |
| Janssen Global Services, LLC | $1,500.00 | 2021 | |
| Array Biopharma INC | $1,311.86 | 2020-2024 | Lorbrena, Mektovi, Braftovi |
| Bayer Healthcare Pharmaceuticals INC. | $1,016.48 | 2019-2024 | |
| Janssen Scientific Affairs, LLC | $907.50 | 2022-2024 | Talvey |
| Glaxosmithkline, LLC. | $510.91 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Regeneron Healthcare Solutions, INC. | $494.89 | 2021-2025 | Libtayo |
| Merck Sharp & Dohme LLC | $494.58 | 2019-2025 | Keytruda, Lynparza |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $413.03 | 2019-2025 | Venclexta |
| Astellas Pharma US INC | $390.12 | 2021-2025 | Xtandi, Padcev, Xospata |
| Pfizer INC. | $387.02 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $325.71 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $325.00 | 2019-2025 | Ultomiris |
| Novocure Gmbh | $200.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $175.12 | 2022-2025 | Ninlaro, Fruzaqla |
| Exelixis INC. | $174.61 | 2020-2025 | Cabometyx |
| Stemline Therapeutics INC. | $149.31 | 2023-2025 | Orserdu |
| Genzyme Corporation | $122.65 | 2020-2024 | |
| Genentech USA, INC. | $116.00 | 2019-2024 | Tecentriq, Rozlytrek, Avastin |
| E.R. Squibb & Sons, L.L.C. | $115.00 | 2019-2022 | |
| Daiichi Sankyo INC. | $114.48 | 2019-2025 | Injectafer, Enhertu |
| Beigene USA, INC. | $96.43 | 2022-2024 | Brukinsa |
| Asd Specialty Healthcare, LLC | $89.68 | 2022 | |
| Aveo Pharmaceuticals, INC. | $87.41 | 2022-2024 | |
| Immunogen, INC. | $80.49 | 2023-2024 | Elahere, Elahere |
| Jazz Pharmaceuticals INC. | $72.01 | 2024-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $69.29 | 2021-2022 | |
| Adc Therapeutics America, INC. | $63.39 | 2022-2024 | |
| Medtronic, INC. | $57.15 | 2024-2025 | Osteocool Rf Ablation System |
| Incyte Corporation | $52.44 | 2019-2024 | Jakafi |
| Cti Biopharma Corp. | $39.32 | 2023 | Vonjo |
| Puma Biotechnology, INC. | $36.85 | 2024 | |
| Deciphera Pharmaceuticals INC. | $30.28 | 2021-2022 | |
| Mirati Therapeutics, INC. | $30.06 | 2023-2024 | Krazati |
| Pharmaand Gmbh | $29.41 | 2025 | Rubraca |
| Tolmar, INC. | $29.41 | 2025 | Rubraca, Eligard |
| Coherus Oncology, INC. | $28.37 | 2021-2023 | |
| Caris Mpi, INC. | $24.96 | 2025 | Mi Cancer Seek |
| Rigel Pharmaceuticals, INC. | $24.72 | 2020 | |
| Geron Corporation | $23.80 | 2025 | Rytelo |
| Sobi, INC | $22.99 | 2025 | |
| Adaptive Biotechnologies Corporation | $22.12 | 2022 | |
| Tesaro, INC. | $21.67 | 2019 | |
| Genmab U.S., INC. | $20.35 | 2024 | Epkinly |
| Blueprint Medicines Corporation | $19.41 | 2021 | |
| G1 Therapeutics, INC. | $18.63 | 2023 | Cosela |
| Agios Pharmaceuticals, INC. | $18.61 | 2025 | Pyrukynd |
| Ipsen Biopharmaceuticals, INC | $18.20 | 2024 | Onivyde |
| Karyopharm Therapeutics INC. | $17.82 | 2024 | Xpovio |
| Pharmacosmos Therapeutics INC. | $16.43 | 2024 | Monoferric |
| Clovis Oncology, INC. | $15.33 | 2021 | |
| Servier Pharmaceuticals LLC | $14.73 | 2021 | |
| Medtronic USA, INC. | $13.47 | 2019 | |
| Global Blood Therapeutics, INC. | $11.89 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$26,610.62 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Sumrall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.